These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23209624)

  • 41. Seasonal influenza vaccines.
    Fiore AE; Bridges CB; Cox NJ
    Curr Top Microbiol Immunol; 2009; 333():43-82. PubMed ID: 19768400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(19):2989-98. PubMed ID: 22386746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P; Moro PL; Ng C; Dores GM; Lewis P; Cano M
    Vaccine; 2019 Mar; 37(11):1516-1520. PubMed ID: 30739795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adverse events reported following live, cold-adapted, intranasal influenza vaccine.
    Izurieta HS; Haber P; Wise RP; Iskander J; Pratt D; Mink C; Chang S; Braun MM; Ball R
    JAMA; 2005 Dec; 294(21):2720-5. PubMed ID: 16333007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
    Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany.
    Falkenhorst G; Harder T; Remschmidt C; Terhardt M; Zepp F; Ledig T; Wicker S; Keller-Stanislawski B; Mertens T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Nov; 56(11):1557-64. PubMed ID: 24170085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.
    Martin D; Menschik D; Bryant-Genevier M; Ball R
    Drug Saf; 2013 Jul; 36(7):547-56. PubMed ID: 23657824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
    King JC; Fast PE; Zangwill KM; Weinberg GA; Wolff M; Yan L; Newman F; Belshe RB; Kovacs A; Deville JG; Jelonek M;
    Pediatr Infect Dis J; 2001 Dec; 20(12):1124-31. PubMed ID: 11740317
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.
    Rosenberg M; Sparks R; McMahon A; Iskander J; Campbell JD; Edwards KM
    Vaccine; 2009 Jul; 27(32):4278-83. PubMed ID: 19450636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010.
    Greene SK; Rett M; Weintraub ES; Li L; Yin R; Amato AA; Ho DT; Sheikh SI; Fireman BH; Daley MF; Belongia EA; Jacobsen SJ; Baxter R; Lieu TA; Kulldorff M; Vellozzi C; Lee GM
    Am J Epidemiol; 2012 Jun; 175(11):1100-9. PubMed ID: 22582210
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ
    Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317
    [TBL] [Abstract][Full Text] [Related]  

  • 53. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project.
    Lee GM; Greene SK; Weintraub ES; Baggs J; Kulldorff M; Fireman BH; Baxter R; Jacobsen SJ; Irving S; Daley MF; Yin R; Naleway A; Nordin JD; Li L; McCarthy N; Vellozzi C; Destefano F; Lieu TA;
    Am J Prev Med; 2011 Aug; 41(2):121-8. PubMed ID: 21767718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma.
    Nordin JD; Vazquez-Benitez G; Olsen A; Kuckler LC; Gao AY; Kharbanda EO
    Vaccine; 2019 Jul; 37(30):4055-4060. PubMed ID: 31196683
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.
    Englund JA; Walter E; Black S; Blatter M; Nyberg J; Ruben FL; Decker MD;
    Pediatr Infect Dis J; 2010 Feb; 29(2):105-10. PubMed ID: 19934787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines.
    Weinberg A; Song LY; Fenton T; Nachman SA; Read JS; Patterson-Bartlett J; Levin MJ
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):51-9. PubMed ID: 20059397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inactivated influenza virus vaccines: the future of TIV and QIV.
    Schotsaert M; García-Sastre A
    Curr Opin Virol; 2017 Apr; 23():102-106. PubMed ID: 28505524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009.
    Moro PL; Broder K; Zheteyeva Y; Walton K; Rohan P; Sutherland A; Guh A; Haber P; Destefano F; Vellozzi C
    Am J Obstet Gynecol; 2011 Feb; 204(2):146.e1-7. PubMed ID: 20965490
    [TBL] [Abstract][Full Text] [Related]  

  • 59. OAE-based data mining and modeling analysis of adverse events associated with three licensed HPV vaccines.
    Zi W; Yang Q; Su J; He Y; Xie J
    Heliyon; 2022 Nov; 8(11):e11515. PubMed ID: 36411908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season.
    Tennis P; Toback SL; Andrews EB; McQuay LJ; Ambrose CS
    Vaccine; 2012 Sep; 30(42):6099-102. PubMed ID: 22841479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.